A new oridonin analog suppresses triple-negative breast cancer cells and tumor growth via the induction of death receptor 5

Jing Wu, Ye Ding, Chuan Huizhi Chen, Zhongmei Zhou, Chunyong Ding, Haiying Chen, Jia Zhou, Ceshi Chen

Research output: Contribution to journalArticle

32 Citations (Scopus)

Abstract

Triple-negative breast cancer (TNBC) remains the leading cause of death among women with breast cancer worldwide. Oridonin is a natural anti-cancer compound that is isolated from the traditional Chinese herb Rabdosia rubescens. However, the antitumor efficacies of oridonin in the treatments of TNBC and other cancers are far from ideal. In this study, we investigated a series of newly designed oridonin analogs in terms of their actions against HCC1806 and HCC1937 TNBC cell lines and identified CYD-6-28, which significantly inhibits cancer cell proliferation and induces G2/M-phase cell cycle arrest and apoptosis. CYD-6-28 induces the expression of p21 and the cleavage of caspase-3, -7, -8 and PARP and inhibits the expression levels of Cyclin D1, FLIPL and XIAP. CYD-6-28 also inhibits the activations of STAT3 and AKT and induces the activation of ERK. We demonstrated that CYD-6-28 induces apoptosis at least partially by inducing the expression of death receptor 5 (DR5). Finally, CYD-6-28 significantly suppresses HCC1806 xenograft tumor growth in nude mice at 5 mg/kg without affecting body weight. Taken together, these results indicate that CYD-6-28 has the potential to be developed as a therapeutic agent to treat TNBC.

Original languageEnglish (US)
Pages (from-to)393-402
Number of pages10
JournalCancer Letters
Volume380
Issue number2
DOIs
StatePublished - Oct 1 2016

Fingerprint

Triple Negative Breast Neoplasms
TNF-Related Apoptosis-Inducing Ligand Receptors
Breast Neoplasms
Growth
Neoplasms
Isodon
Apoptosis
M Phase Cell Cycle Checkpoints
Caspase 7
G2 Phase
Cyclin D1
Heterografts
Nude Mice
Caspase 3
Cause of Death
Body Weight
Cell Proliferation
Cell Line
oridonin
Therapeutics

Keywords

  • Apoptosis
  • Death receptor 5 (DR5)
  • Oridonin analog
  • Therapy
  • Triple-negative breast cancer

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

A new oridonin analog suppresses triple-negative breast cancer cells and tumor growth via the induction of death receptor 5. / Wu, Jing; Ding, Ye; Chen, Chuan Huizhi; Zhou, Zhongmei; Ding, Chunyong; Chen, Haiying; Zhou, Jia; Chen, Ceshi.

In: Cancer Letters, Vol. 380, No. 2, 01.10.2016, p. 393-402.

Research output: Contribution to journalArticle

Wu, Jing ; Ding, Ye ; Chen, Chuan Huizhi ; Zhou, Zhongmei ; Ding, Chunyong ; Chen, Haiying ; Zhou, Jia ; Chen, Ceshi. / A new oridonin analog suppresses triple-negative breast cancer cells and tumor growth via the induction of death receptor 5. In: Cancer Letters. 2016 ; Vol. 380, No. 2. pp. 393-402.
@article{6ae7c2472267447186d56a0294ff066b,
title = "A new oridonin analog suppresses triple-negative breast cancer cells and tumor growth via the induction of death receptor 5",
abstract = "Triple-negative breast cancer (TNBC) remains the leading cause of death among women with breast cancer worldwide. Oridonin is a natural anti-cancer compound that is isolated from the traditional Chinese herb Rabdosia rubescens. However, the antitumor efficacies of oridonin in the treatments of TNBC and other cancers are far from ideal. In this study, we investigated a series of newly designed oridonin analogs in terms of their actions against HCC1806 and HCC1937 TNBC cell lines and identified CYD-6-28, which significantly inhibits cancer cell proliferation and induces G2/M-phase cell cycle arrest and apoptosis. CYD-6-28 induces the expression of p21 and the cleavage of caspase-3, -7, -8 and PARP and inhibits the expression levels of Cyclin D1, FLIPL and XIAP. CYD-6-28 also inhibits the activations of STAT3 and AKT and induces the activation of ERK. We demonstrated that CYD-6-28 induces apoptosis at least partially by inducing the expression of death receptor 5 (DR5). Finally, CYD-6-28 significantly suppresses HCC1806 xenograft tumor growth in nude mice at 5 mg/kg without affecting body weight. Taken together, these results indicate that CYD-6-28 has the potential to be developed as a therapeutic agent to treat TNBC.",
keywords = "Apoptosis, Death receptor 5 (DR5), Oridonin analog, Therapy, Triple-negative breast cancer",
author = "Jing Wu and Ye Ding and Chen, {Chuan Huizhi} and Zhongmei Zhou and Chunyong Ding and Haiying Chen and Jia Zhou and Ceshi Chen",
year = "2016",
month = "10",
day = "1",
doi = "10.1016/j.canlet.2016.06.024",
language = "English (US)",
volume = "380",
pages = "393--402",
journal = "Cancer Letters",
issn = "0304-3835",
publisher = "Elsevier Ireland Ltd",
number = "2",

}

TY - JOUR

T1 - A new oridonin analog suppresses triple-negative breast cancer cells and tumor growth via the induction of death receptor 5

AU - Wu, Jing

AU - Ding, Ye

AU - Chen, Chuan Huizhi

AU - Zhou, Zhongmei

AU - Ding, Chunyong

AU - Chen, Haiying

AU - Zhou, Jia

AU - Chen, Ceshi

PY - 2016/10/1

Y1 - 2016/10/1

N2 - Triple-negative breast cancer (TNBC) remains the leading cause of death among women with breast cancer worldwide. Oridonin is a natural anti-cancer compound that is isolated from the traditional Chinese herb Rabdosia rubescens. However, the antitumor efficacies of oridonin in the treatments of TNBC and other cancers are far from ideal. In this study, we investigated a series of newly designed oridonin analogs in terms of their actions against HCC1806 and HCC1937 TNBC cell lines and identified CYD-6-28, which significantly inhibits cancer cell proliferation and induces G2/M-phase cell cycle arrest and apoptosis. CYD-6-28 induces the expression of p21 and the cleavage of caspase-3, -7, -8 and PARP and inhibits the expression levels of Cyclin D1, FLIPL and XIAP. CYD-6-28 also inhibits the activations of STAT3 and AKT and induces the activation of ERK. We demonstrated that CYD-6-28 induces apoptosis at least partially by inducing the expression of death receptor 5 (DR5). Finally, CYD-6-28 significantly suppresses HCC1806 xenograft tumor growth in nude mice at 5 mg/kg without affecting body weight. Taken together, these results indicate that CYD-6-28 has the potential to be developed as a therapeutic agent to treat TNBC.

AB - Triple-negative breast cancer (TNBC) remains the leading cause of death among women with breast cancer worldwide. Oridonin is a natural anti-cancer compound that is isolated from the traditional Chinese herb Rabdosia rubescens. However, the antitumor efficacies of oridonin in the treatments of TNBC and other cancers are far from ideal. In this study, we investigated a series of newly designed oridonin analogs in terms of their actions against HCC1806 and HCC1937 TNBC cell lines and identified CYD-6-28, which significantly inhibits cancer cell proliferation and induces G2/M-phase cell cycle arrest and apoptosis. CYD-6-28 induces the expression of p21 and the cleavage of caspase-3, -7, -8 and PARP and inhibits the expression levels of Cyclin D1, FLIPL and XIAP. CYD-6-28 also inhibits the activations of STAT3 and AKT and induces the activation of ERK. We demonstrated that CYD-6-28 induces apoptosis at least partially by inducing the expression of death receptor 5 (DR5). Finally, CYD-6-28 significantly suppresses HCC1806 xenograft tumor growth in nude mice at 5 mg/kg without affecting body weight. Taken together, these results indicate that CYD-6-28 has the potential to be developed as a therapeutic agent to treat TNBC.

KW - Apoptosis

KW - Death receptor 5 (DR5)

KW - Oridonin analog

KW - Therapy

KW - Triple-negative breast cancer

UR - http://www.scopus.com/inward/record.url?scp=84978640737&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84978640737&partnerID=8YFLogxK

U2 - 10.1016/j.canlet.2016.06.024

DO - 10.1016/j.canlet.2016.06.024

M3 - Article

VL - 380

SP - 393

EP - 402

JO - Cancer Letters

JF - Cancer Letters

SN - 0304-3835

IS - 2

ER -